论文部分内容阅读
１６名汉族健康志愿者进行Ｓ－美芬妥英４’－羟化代谢分型，１３名为强代谢者（ＥＭｓ），３名为弱代谢者（ＰＭｓ）。口服苯妥英１００ｍｇ，应用ＨＰＬＣ法测定服药后２４ｈ尿中苯妥英和４’－羟苯妥英（４’－ＯＨ－ＰＨＴ）的排泄量。１３名Ｓ－美芬妥英强代谢者Ｌｇ苯妥英／４’－羟苯妥英比值为－２．１７±０．２６；３名弱代谢者为－２．２７±０．１０，两组无显著性差异Ｐ＞０．０５）。１６名受试者Ｓ－美芬妥英和苯妥英的羟化代谢比值无相关性（ｒ＝－０．１０８，Ｐ＞０．００５）。本文结果表明，Ｓ－美芬妥英和苯妥英虽同为乙内酰脲类抗癫痫药，化学结构和羟化反应均相似，但在人体内不属同一羟化途径代谢，无交叉代谢障碍。
Thirty-six Han healthy volunteers performed 4’-hydroxylation of S-mephenytoin, 13 were metabolically metabolized (EMs) and 3 were weak metabolizers (PMs). Oral phenytoin 100mg, HPLC determination of urinary phenytoin and 4’-hydroxyphenytoin (4’-OH-PHT) excretion 24 hours after taking the drug. Thirteen S-mephenytoin strong metabolizer Lg phenytoin / 4’-hydroxyphenytoin ratio was -2.17 ± 0.26; three poor metabolizers were -2.27 ± 0.10, no significant difference between the two groups Difference P> 0.05). There was no correlation between the metabolic ratio of S-mephenytoin and phenytoin (r = -0.108, P> 0.005) in 16 subjects. The results show that, S-mephenytoin and phenytoin, although hydantoin antiepileptic drugs, chemical structure and hydroxylation are similar, but in the human body is not the same hydroxylation pathway metabolism, no cross-metabolic disorders.